Neutral. In line with expectations. We expect Avidity related issuance reasonably soon.
• Sales $13.9bn +7% CER
• Core Op Income $5.5bn +7%
• Quarterly Op Margin 39.3%; 41.2% for 9M.
• FCF Q3 $6.2bn; 9M $15.9bn +26% y/y
• Shareholder-friendly use of the free cashflow. $7.8bn dividend in H1 and $15bn share buybacks completed in Q3. Has commenced new $10bn buyback.
• Avidity $12bn takeover announced yesterday. Tourmaline Bio $1.4bn deal has closed. Issuance expected soon.
• 2025 Guidance reaffirmed. Sales high single digit; Core Op Income Low Teens. Guidance assumes Q4 slowdown vs prior year.
• 7 "Priority Brands" +35% cc Growth. Kisqali +68% to $1.3bn; Kesimpta +44% to $1.2bn
Find more articles and bullets on these widgets:
While we heard the monetary policy views of 6 of 12 current FOMC voters this week, there were no real surprises. We go through all of the relevant FOMC communications in full in our Macro Weekly PDF.
2025 FOMC Voters:
Non-2025 Voters:
We've just published our US Macro Weekly - Download Full Report Here
